



Lessening Organ Dysfunction with VITamin C

LOVIT and LOVIT-C^{COVID}

Newsletter

Volume 3, Issue 6 – July 22, 2021


LOVIT Completes Enrolment!

We are thrilled to report that we have closed enrolment for the LOVIT trial after reaching our sample size. A total of 872 patients were randomized in the LOVIT trial. We would like to thank our eight sites in New Zealand who enrolled 86 patients! Thank you for your contributions to the LOVIT trial!

Next Steps for LOVIT

We will continue to work closely with everyone to ensure timely data analysis and dissemination of findings. To accomplish this, **please submit all in-hospital data and replies to all queries by September 15, 2021.** We will begin data cleaning in September and will issue queries on any inconsistent data. Please continue to submit data from the 6-month visits as you complete them. We look forward to sharing the results of the trial with you in early 2022!

LOVIT - Enrolment Over Time




LOVIT Enrolment by Site and

Data Entry and Validation Summary

The different colours on the graph show the status of the data entry and queries resolution. Quality Control reports will be sent weekly from now. As you can see, we are in great shape. Thanks for your collaboration!



Data Entry and Validation Summary (as of July 1, 2021)





Lessening Organ
Dysfunction with
VITamin C

LOVIT and LOVIT-C^{COVID}

Newsletter

Volume 3, Issue 6 – July 22, 2021

LOVIT-COVID Enrolment

Enrolment continues for LOVIT-COVID. We have enrolled 233 patients into LOVIT-COVID across nine clinical sites in Canada. There were eight patients enrolled in June. We have recently initiated three sites: Oakville Trafalgar Memorial Hospital, Ottawa General Hospital, and Ottawa Civic Hospital.



LOVIT-COVID and LOVIT Site Payments

We will issue the site payments for LOVIT and LOVIT-COVID in mid-September. Please submit all outstanding data and replies to all queries before this date to maximize your payment. If you have any questions about your query report, please do not hesitate to contact us.

**By combining all COVID-19 patients from LOVIT, LOVIT-COVID and REMAP-CAP Vitamin C domain, we have more than 1,000 participants!
This data will be analyzed as part of a master protocol.**

Contact us if you have
questions

Marie-Hélène Masse
Project leader
1-819-346-1110 ext. 14173
marie-helene.masse3@usherbrooke.ca

Julie Ménard
Co-Project leader
1-819-346-1110 ext. 13534
julie.menard.ciussse-chus@ssss.gouv.qc.ca

Visit our website: <http://lovit.ccctg.ca/>

We LOV(e) working with you!